BIIB

SEC source: 0001127602-22-004993 · form4.xml · nonDerivative · entry 3

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004993 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,520

SEC source: 0001127602-22-004993 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004989 · form4.xml · derivative · entry 9

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,818

Underlying: Common Stock · 2,480 shares

Expires 2023-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004989 · form4.xml · derivative · entry 8

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,298

Underlying: Common Stock · 1,336 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004989 · form4.xml · derivative · entry 7

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,395 shares

Expires 2022-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004989 · form4.xml · derivative · entry 6

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,395

Underlying: Common Stock · 1,261 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 5

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,262

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.

SEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 4

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,451

SEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 3

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 2

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,708

SEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 1

Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004986 · form4.xml · derivative · entry 9

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,564

Underlying: Common Stock · 8,163 shares

Expires 2023-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004986 · form4.xml · derivative · entry 8

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,727

Underlying: Common Stock · 4,395 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004986 · form4.xml · derivative · entry 7

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,205 shares

Expires 2022-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004986 · form4.xml · derivative · entry 6

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,205

Underlying: Common Stock · 4,321 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 5

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,816.188

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.

SEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 4

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,515.188

SEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 3

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,465.188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 2

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,070.188

SEC source: 0001127602-22-004986 · form4.xml · nonDerivative · entry 1

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,987.188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004988 · form4.xml · derivative · entry 4

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,006

Underlying: Common Stock · 651 shares

Expires 2023-02-12

F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004988 · form4.xml · derivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,657

Underlying: Common Stock · 351 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004988 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,335

SEC source: 0001127602-22-004988 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Alzheimer's Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,457

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004991 · form4.xml · derivative · entry 9

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,516

Underlying: Common Stock · 1,633 shares

Expires 2023-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004991 · form4.xml · derivative · entry 8

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,149

Underlying: Common Stock · 879 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004991 · form4.xml · derivative · entry 7

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,505 shares

Expires 2022-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004991 · form4.xml · derivative · entry 6

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,505

Underlying: Common Stock · 793 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,447.6165

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 21, 2022.

SEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,031.6165

SEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,421.6165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,542.6165

SEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,820.6165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004987 · form4.xml · derivative · entry 9

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506

Underlying: Common Stock · 326 shares

Expires 2023-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004987 · form4.xml · derivative · entry 8

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 832

Underlying: Common Stock · 176 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004987 · form4.xml · derivative · entry 7

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 189 shares

Expires 2022-02-12

F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004987 · form4.xml · derivative · entry 6

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189

Underlying: Common Stock · 99 shares

Expires 2022-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 5

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,458.348

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022.

SEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 4

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,543.348

SEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,594.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,418.348

SEC source: 0001127602-22-004987 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,453.348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004984 · form4.xml · derivative · entry 4

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756

Underlying: Common Stock · 489 shares

Expires 2023-02-12

F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004984 · form4.xml · derivative · entry 3

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,245

Underlying: Common Stock · 263 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-22-004984 · form4.xml · nonDerivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,396.89

SEC source: 0001127602-22-004984 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,488.89

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-22-004811 · form4.xml · derivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,725

Underlying: Common Stock · 7,725 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004806 · form4.xml · derivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,475

Underlying: Common Stock · 6,475 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-22-004794 · form4.xml · derivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2025-02-10

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.